Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Genomic predictors of sensitivity to chemotherapy and immunotherapy in cholangiocarcinoma.
Authors
Riya Jayesh Patel
Roswell Park Cancer Institute, Buffalo, NY
Riya Jayesh Patel , Spencer Rosario , Sahithi Sonti , Ankita Kapoor , Deepak Vadehra , Sarbajit Mukherjee , Kannan Thanikachalam , Renuka V. Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 540)
DOI
10.1200/JCO.2024.42.3_suppl.540
Abstract #
540
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells.
First Author: Frances Jenkins Bennett
Poster
2024 ASCO Annual Meeting
Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset.
First Author: Pushkar Mutha
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma.
First Author: Mariela A. Blum Murphy